ProLung, Inc.

About ProLung Inc

This author has not yet filled in any details.
So far ProLung Inc has created 25 entries.

ProLung Installs Chief Accounting Officer

Salt Lake City, UT, May 11, 2017 — ProLung, Inc., the leader in innovative predictive analytics technology and non-invasive tests for lung cancer, announced today the promotion of Aaron Stout to Chief Accounting Officer. Mr. Stout previously served as the Controller for ProLung.

“We are enthusiastic about the experience Mr. Stout brings to the executive management team,” stated Steve Eror, President and CEO, ProLung. “His role and experience will be crucial as ProLung prepares to enter a phase of high growth and expansion.”

Mr. Stout comes to ProLung with more than 10 years of finance and operations experience with multiple public and privately held companies in the manufacturing and medical device industries where he has successfully raised capital in debt and equity markets.  Prior to joining ProLung, Mr. Stout was the Controller of Amedica Corp, where he served from March 2014 to April 2017 and was responsible for a wide range of financial and accounting services. He served as a Senior Financial Accountant with America First Credit Union from August 2011 to April 2014. Mr. Stout has a Masters of Professional Accounting from Weber State University.

“I can’t imagine a more exciting time to be part of ProLung,” Mr. Stout said. “I look forward to working with Steve and the entire ProLung leadership team to ensure a successful and capital-efficient business.”

About ProLung, Inc.

ProLung’s mission is to make a difference in time for lung cancer patients. ProLung is a leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer. The Company develops, tests, and commercializes solutions which may shorten the time to diagnosis and expand the therapeutic window for lung cancer patients. ProLung’s predictive analytics platform for lung cancer risk stratification is […]

By |11 May 2017|Uncategorized|Comments Off on ProLung Installs Chief Accounting Officer|

ProLung Names Director of Marketing and Business Development

Salt Lake City, UT, May 11, 2017 — ProLung, Inc., the leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today the promotion of Ryan Snow as the Director of Marketing and Business Development. Mr. Snow has been with the Company for three years and performed in multiple capacities, previously serving as the European Development Director.

“We are excited for Ryan to fulfill his new role as Director of Business Development during this time of rapid growth for the Company” said Steve Eror, President and CEO of ProLung. “Ryan brings a unique perspective and skill set as we approach global markets and regulatory approval in the US.  He has extraordinary international experience that has been transformative for the businesses he supports.”

Mr. Snow received his B.S. degree in Business and Accountancy from the University of Utah David Eccles School of Business. While attending the David Eccles School of Business he was a Student Director at the Lassonde Entrepreneur Institute. Through this experience, he realized his passion for entrepreneurism and commercialization of innovative technologies and solutions. Ryan speaks Spanish and holds international development and sales experience.

About ProLung, Inc.

ProLung’s mission is to make a difference in time for lung cancer patients. ProLung is the leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer. The Company develops, tests, and commercializes solutions which may shorten the time to diagnosis and expand the therapeutic window for lung cancer patients. ProLung’s predictive analytics platform for lung cancer risk stratification is approved for sale in the European Economic Area and for investigational use only in the US.

 

For further information, contact:

Ryan Snow | +1-801-503-9231 | rts@prolunginc.com

Director of Marketing and […]

By |11 May 2017|Uncategorized|Comments Off on ProLung Names Director of Marketing and Business Development|

ProLung, Inc. Announces Closing of Private Placement Transaction with Proceeds of $8.2 million

Salt Lake City, UT, May 11, 2017 — ProLung, Inc., the leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today the successful closing of its private placement. The private offering was expected to raise $5.2 million and was oversubscribed by $3.0 million to a total of $8.2 million.
“ProLung is pleased to announce the successful closing of its private placement,” said Steven Eror, President and CEO of ProLung. “The demand for ProLung stock demonstrates the broad and urgent recognition of the need for a non-invasive predictive analytical test for lung cancer. The ProLung Test is being developed to enable much earlier detection and biopsy for these patients. This could expand the therapeutic window while lowering the cost of current approaches.”
“Investors and strategic partners were impressed with both ProLung’s mission and its progress when the company kicked off their roadshow at the White Hat Life Science Investor Conference in Arizona last September,” shared Joan Koerber-Walker, president & CEO of AZBio. “Lung cancer is the number one killer and patients need new and innovative solutions to help them survive and thrive. Congratulations to the ProLung team on passing this important funding milestone.”
ProLung will use the proceeds from the private placement to finance operations, continue research and development efforts related to its innovative technology, and commercialize the ProLung Test in the US upon regulatory approval from the US Food and Drug Administration.
“It is wonderful to see another Utah life science company successfully raise funds to advance their healthcare solution,” stated Kelly Slone, President and CEO, BioUtah. “ProLung’s accomplishment is another example of the robust and innovative life science community in Utah.”
About ProLung, Inc.
ProLung’s mission is to make a […]

By |11 May 2017|Uncategorized|Comments Off on ProLung, Inc. Announces Closing of Private Placement Transaction with Proceeds of $8.2 million|

ProLung Selected to Participate at Upcoming Cavendish Global Health Impact Forum

Salt Lake City, UT, May 4, 2017, — ProLung, Inc., a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer, announced today it has been selected to present at the upcoming Cavendish Global Health Impact Forum taking place May 7-9, 2017 in Washington, DC, co-hosted with the Virginia Biotechnology Association (VirginiaBio).

As part of ProLung’s awareness campaign to further increase corporate visibility among the scientific, financial, and philanthropic communities, ProLung recently became a member of Cavendish Global.  ProLung will utilize the Cavendish Global platform to educate and further broaden awareness for ProLung’s mission to help save the lives of historically underserved lung cancer patients. The Company is fulfilling its mission through its non-invasive predictive analytics platform, the ProLung Test which aids in the risk stratification of indeterminate pulmonary nodules.

“We are honored to be selected to present at Cavendish’s unique event, and it is further recognition of our innovative approach to addressing the need for early detection of lung cancer with our breakthrough predictive analytics’ device.  Given that lung cancer is the leading cause of cancer deaths worldwide, killing more individuals than colorectal, breast, pancreatic, and prostate cancers combined, the need for early detection has significant impact,” stated Steven Eror, President and CEO of ProLung.  “ProLung recently became a member of Cavendish Global and is looking forward to its participation in the organization.  Its members include many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people globally.”

Michael Moffat, Cavendish co-founder and Chairman explains, “With the help of our expert advisors, we conduct a global search of research institutions and […]

By |4 May 2017|Uncategorized|Comments Off on ProLung Selected to Participate at Upcoming Cavendish Global Health Impact Forum|

ProLung Announces the Appointment of Dr. Robin L. Smith to its Board of Directors

Salt Lake City, Utah, February 16, 2017 – ProLung, a predictive analytics and risk stratification company that has developed a novel, cost effective, and non-invasive test to identify cancerous and noncancerous lung nodules, announced today that Robin L. Smith, MD, MBA, has joined the Company’s Board of Directors.

“ProLung is pleased to have the guidance of Dr. Smith as we complete our pivotal trial enrollment and begin positioning the company toward commercialization,” stated Steven Eror, CEO and founder of ProLung. “Her extensive experience as a thought leader in the healthcare space will be of great benefit to our shareholders and patients as we reach significant milestones,” added Todd Morgan, Chairman of the Board.

“I am pleased to be joining ProLung at this exciting moment,” stated Dr. Smith. “I believe there is an urgent need in the practice of pulmonology to assist practitioners with an objective, non-radiating, and non-invasive tool. ProLung’s technology is already approved in Europe and is currently saving lives.”

Dr. Smith serves as Chairman of the Board for MYnd Analytics, is a director of Rockwell Medical and serves as a director of Bioxcel Corporation. She is Chairman of the Board of the Cura Foundation and Stem for Life Foundation. She also serves on the international board of Stanford Health and is Vice President of the STOQ Foundation of the Vatican dedicated to the dialogue between science and faith. Dr. Smith earned her M.D. from Yale University and M.B.A. from the Wharton School of Business.

About ProLung

ProLung’s mission is to make a difference in time for lung cancer patients. ProLung is a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer. The Company develops, tests, and commercializes solutions which may […]

By |16 February 2017|Uncategorized|Comments Off on ProLung Announces the Appointment of Dr. Robin L. Smith to its Board of Directors|

Shareholder Update Letter

January 15, 2017

 

Happy New Year from ProLung!

2016 has been a spectacular year.

To achieve our research goals more rapidly, we assembled the most extensive team of clinical investigators of lung cancer in pulmonology.

This speeds the clinical evaluation required for FDA market approval, sets the stage for rapid commercial rollout, insurance reimbursement and commercial growth. The quality of the physician investigators in the US and in Europe is beyond what we could have imagined at this point last year.  These clinics, now active in ProLung’s pivotal trial, have choices in what to research.  As shareholders, we are deeply grateful for each clinic’s commitment.  Today, lung cancer remains the leading cause of cancer death for men and women.  With the help from these champion clinicians, a better pathway is just around the corner.   2016 brought the golden age of pulmonology.  Here are the clinics that are bringing ProLung and their patients into that age by participating in ProLung research or offering the ProLung test to patients (Europe):

Azienda Ospedaliera Universitaria San Martino di Genova (pulmonology)
Azienda Ospedaliera Universitaria San Martino di Genova (thoracic surgery)
Azienda Ospedaliero Universitaria Maggiore della Carità di Novara
Azienda Ospedaliero Universitaria Careggi
Chicago Chest Center Interventional Pulmonology and Thoracic Disease
Greater Baltimore Medical Center
Harvard University at Beth Israel Deaconess Hospital
Henry Ford Hospital
Huntsman Cancer Institute at the University of Utah
Intermountain Healthcare
Johns Hopkins School of Medicine
Loyola University, Providence Health Center
Lungenklinik Löwenstein
M D Anderson Cancer Center
Medical University of South Carolina
Northwestern Memorial Hospital
Stanford Healthcare
Università Politecnica della Marche
Universitätsspital Basel
University of California at Los Angeles (pulmonology)
University of California at Los Angeles (radiology)
University of California at San Diego
University of Geneva
University of Minnesota […]

By |15 January 2017|Uncategorized|Comments Off on Shareholder Update Letter|

Gregory C. Simon Meeting

Steven C. Eror, President and CEO, meets with Gregory C. Simon, White House Cancer Moonshot Task Force, Executive Director in the Office of the Vice President.

By |10 December 2016|Uncategorized|Comments Off on Gregory C. Simon Meeting|

ProLung CEO Interviewed at the BIO Investor Forum

San Francisco, California, Wednesday October 19, 2016

 

By |2 November 2016|Uncategorized|Comments Off on ProLung CEO Interviewed at the BIO Investor Forum|

ProLung Interviewed by National Healthcare Reporter

 

12/10/2016

   ProLungDX seeks funds for cancer test; sees eventual IPO – CEO 
   Proprietary Intelligence

Story

ProLungDX, a maker of lung cancer detection devices, is looking to raise USD 5.25m from high net worth investors for US commercial development in advance of an expected initial public offering or trade sale, according to CEO Steven Eror.
The Salt Lake City, Utah-based privately held company, which is conducting US clinical trials for its EPN Scan lung cancer screening device, expects to gain FDA approval next year. The device is already marketed in Europe, having received a CE mark in 2013.
The company, also known as Fresh Medical Laboratories, is already “IPO ready,” said the executive, having reported financial statements for three years. The public reporting began as a result of a potential PIPE deal that never occurred in 2012.
Eror said the current fundraising values the company at USD 30m. Proceeds of the fundraising will be used to continue US clinical trials for the device and to hire a sales force for outreach to hospitals and pulmonary specialists.
The current standard for lung cancer diagnosis is CT screening, which is conducted for several years to determine if a lung abnormality is cancerous. ProLungDX says its non-invasive EPN Scan can determine immediately with a 90% accuracy rate whether an abnormality is cancerous so that potentially lifesaving treatment can be undertaken sooner.
The device “replaces months and years of CT follow-up,” the company said in investor materials.
Eror said the company’s end-goal is a dual IPO and sale process in coming years. The executive said ProLungDx is already in talks with major companies that could buy it which he declined to name. But he said large players that could be interested include Medtronic(NYSE:MDT) and Johnson & Johnson (NYSE:JNJ). In addition, the company is “being courted” by NASDAQ for a potential listing.
“We […]

By |2 November 2016|Uncategorized|Comments Off on ProLung Interviewed by National Healthcare Reporter|

ProLungdx Unveils its EPN Scan® at the BIO Investor Forum: Long-Awaited Test for those at Risk of Lung Cancer

Salt Lake City, UT, USA, October 13, 2016 – ProLungdx™ today announced plans to present its leading-edge innovation for patients at risk of lung cancer during the 2016 BIO Investor Forum in San Francisco, California October 18 and 19, 2016.

For the first time in an international biotech investment conference, prospective investors will have the opportunity to review ProLungdx’s Electro Pulmonary Nodule Scan™ or EPN Scan, a device designed to make a difference in time for patients who have the potential for cancer in an indeterminate lung nodule identified by a CT screen or incidental finding. “It is distressing that patients wait months or even years to determine if their lung nodule is cancer,” said Steven Eror, ProLungdx’s CEO. “This waiting time drastically reduces the treatment window for therapy.  The EPN Scan’s purpose is to make a difference in time by reducing or eliminating the wait.”

ProLungdx was selected to present alongside some of the most promising life science companies at the BIO Investor Forum. “The BIO Investor Forum, now in its 15th year, is designed to help biotechnology companies find sources of capital. Attendees have opportunities to learn about the latest investment trends as well as showcase their company to qualified investors,” said Theresa Brady of the BIO Investor Forum.

The EPN Scan is nearing completion of its pivotal work with 14 premier US cancer centers. These represent a consensus of thought leaders seeking to accelerate the assessment of lung cancer risk in pulmonology, radiology, and thoracic surgery. Concern has rapidly increased following this year’s introduction and national reimbursement coverage of the low-dose CT chest screen for lung cancer. The screen has been shown to have a 96% false positive rate for cancer and highlights the […]

By |13 October 2016|Uncategorized|Comments Off on ProLungdx Unveils its EPN Scan® at the BIO Investor Forum: Long-Awaited Test for those at Risk of Lung Cancer|